Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Texas Department of State Health Services | OTHER |
| Usona Institute | OTHER |
| AIM Youth Mental Health | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The principal investigator for this study plans to build upon the psilocybin-assisted therapy intervention used in prior completed trials to conduct an open-label trial of two psilocybin administration sessions combined with psychotherapy to investigate the safety, tolerability, and clinical efficacy of psilocybin-assisted therapy for the treatment of PTSD in US Veterans.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Psilocybin-assisted therapy | Experimental | Participants will enter a 5-week participation phase, which includes 3 preparatory sessions, 2 dosing days, and 4 integration sessions. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Psilocybin 15mg | Drug | Each participant will have a low dose (15 mg) psilocybin session to establish basic skills with session format, psilocybin effects, and continue to build rapport with session facilitators. Given the potential intensity of the psilocybin and the reality of experiencing significant trauma memories, the purpose of the first psilocybin session is to familiarize participants with the drug effects that may be encountered at a higher dose of psilocybin. The first psilocybin session will also allow for assessment of both the suitability of each participant to the study procedures and drug effects, and the safety of administering a higher dose to each participant. |
| Measure | Description | Time Frame |
|---|---|---|
| Safety of psilocybin-assisted therapy for PTSD | Safety as measured by Adverse Event Reporting | Baseline to 6-month follow up |
| Safety of psilocybin-assisted therapy for PTSD | Safety as measured by changes in suicidal ideation on the Columbia Suicide Safety Rating Scale (CSSRS). This section of the measure is assessed on a scale of 0 to 25, with higher scores indicating greater intensity of suicidal ideation. | Baseline to 6-month follow up |
| Efficacy of psilocybin-assisted therapy for PTSD | Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score. This measure is assessed on a scale of 0 to 80, with higher scores reflecting increased severity of PTSD symptoms. | Baseline to 6-month follow up |
| Measure | Description | Time Frame |
|---|---|---|
| Self-reported clinical efficacy of psilocybin-assisted therapy for PTSD symptoms | Change in self-reported PTSD Checklist 5 (PCL-5) scores. This measure is assessed on a scale of 0 to 80, with higher scores reflecting increased severity of PTSD symptoms. | Baseline to 6-month follow up |
| Self-reported clinical efficacy of psilocybin-assisted therapy for depressive symptoms |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Resting-State Functional Connectivity | The effect of psilocybin-assisted therapy on functional connectivity networks using resting-state functional magnetic resonance imaging (MRI) | Baseline to 6-month follow up |
Inclusion Criteria:
Exclusion Criteria:
General medical exclusion criteria:
Psychiatric Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lynnette A. Averill, Ph.D. | Contact | ‪(832) 271-6615 | emerging@bcm.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Baylor College of Medicine | Recruiting | Houston | Texas | 77030 | United States |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Dec 11, 2024 | Mar 14, 2025 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Dec 11, 2024 | Mar 14, 2025 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D013313 | Stress Disorders, Post-Traumatic |
| D014947 | Wounds and Injuries |
| ID | Term |
|---|---|
| D040921 | Stress Disorders, Traumatic |
| D000068099 | Trauma and Stressor Related Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D011562 | Psilocybin |
| ID | Term |
|---|---|
| D026121 | Indole Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D007211 | Indoles |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Psilocybin 25mg | Drug | The second psilocybin session will utilize a high dose (25mg) and take place approximately 2 weeks after the first psilocybin session. |
|
Changes in self-reported Quick Inventory of Depression Severity (QIDS) scores. This measure is assessed on a scale of 0 to 27, with higher scores reflecting increased severity of depressive symptoms. |
| Baseline to 6-month follow up |
| Self-reported clinical efficacy of psilocybin-assisted therapy for anxiety symptoms | Changes in self-reported Generalized Anxiety Disorder-7 (GAD-7) scores. This measure is assessed on a scale of 0 to 21, with higher scores reflecting increased severity of anxiety symptoms. | Baseline to 6-month follow up |
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D014363 | Tryptamines |
| D054836 | Indolizidines |
| D007212 | Indolizines |